Literature DB >> 21448687

Inflammatory activation in an unselected population of subjects with atrial fibrillation: links with structural heart disease, atrial remodeling and recent onset.

Pier Luigi Pellegrino1, Natale Daniele Brunetti, Luisa De Gennaro, Luigi Ziccardi, Massimo Grimaldi, Matteo Di Biase.   

Abstract

Previous studies investigated circulating levels of C-reactive protein (CRP) mostly in subjects with paroxysmal atrial fibrillation (AF) and lone AF (LAF). We, therefore, aimed to investigate circulating levels of CRP in patients with new onset AF with particular regards to AF duration, even in the presence of structural heart disease (SHD). CRP levels were evaluated in 96 consecutive patients with new onset AF (50 with LAF and 46 with SHD, 41 with paroxysmal AF (PAF) (<7 days) and 55 persistent AF (>7 days). Patients with AF had higher CRP levels than controls (4.8 ± 6.99 vs. 1.59 ± 1.32 mg/L; p < 0.001). AF patients with SHD had higher CRP levels than LAF patients (7.08 ± 9.19 vs. 2.63 ± 2.47 mg/L; p < 0.01) and control subjects (vs. 1.59 ± 1.32 mg/L; p < 0.001): CRP levels in LAF patients were higher than in controls (p < 0.01). CRP levels were significantly increased in subjects with paroxysmal AF (6.67 ± 9.44 mg/L) with respect to those with persistent AF (3.54 ± 4.44 mg/L, p < 0.05) and controls (1.59 ± 1.32 mg/L, p < 0.001 vs. paroxysmal AF, p < 0.01 vs. persistent AF). Differences related to the presence of LAF and SHD remained significant even after multivariable regression analysis. CRP concentrations significantly correlated with left atrial size(r 0.23, p < 0.05). Increased CRP levels are detectable in patients with AF, proportional to atrial remodeling, recent onset of dysrhythmia and SHD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448687     DOI: 10.1007/s11739-011-0557-z

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  31 in total

1.  Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation.

Authors:  M J Mihm; F Yu; C A Carnes; P J Reiser; P M McCarthy; D R Van Wagoner; J A Bauer
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

Review 2.  New ideas about atrial fibrillation 50 years on.

Authors:  Stanley Nattel
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

3.  Cardiac dysfunction caused by purified human C3a anaphylatoxin.

Authors:  U H del Balzo; R Levi; M J Polley
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

4.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation.

Authors:  A Frustaci; C Chimenti; F Bellocci; E Morgante; M A Russo; A Maseri
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

Review 5.  Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view.

Authors:  P M Ridker
Journal:  Blood Coagul Fibrinolysis       Date:  1999-02       Impact factor: 1.276

6.  C-reactive protein and atrial fibrillation: "evidence for the presence of inflammation in the perpetuation of the arrhythmia".

Authors:  Mónica Acevedo; Ramón Corbalán; Sandra Braun; Jaime Pereira; Carlos Navarrete; Ilse Gonzalez
Journal:  Int J Cardiol       Date:  2005-06-27       Impact factor: 4.164

7.  Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation.

Authors:  Stavroula N Psychari; Thomas S Apostolou; Loukas Sinos; Eftihia Hamodraka; George Liakos; Dimitrios Th Kremastinos
Journal:  Am J Cardiol       Date:  2005-03-15       Impact factor: 2.778

8.  Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.

Authors:  Laurent Fauchier; Bertrand Pierre; Axel de Labriolle; Caroline Grimard; Noura Zannad; Dominique Babuty
Journal:  J Am Coll Cardiol       Date:  2008-02-26       Impact factor: 24.094

9.  Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis.

Authors:  Yoichi Nakamura; Kazufumi Nakamura; Kengo Fukushima-Kusano; Keiko Ohta; Hiromi Matsubara; Tsutomu Hamuro; Chikao Yutani; Tohru Ohe
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

10.  Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.

Authors:  Natale Daniele Brunetti; Guglielmo Maulucci; Grazia Pia Casavecchia; Carlo Distaso; Luisa De Gennaro; Pier Luigi Pellegrino; Matteo Di Biase
Journal:  J Interv Cardiol       Date:  2007-12       Impact factor: 2.279

View more
  5 in total

1.  Atrial fibrillation and kidney disease: insights on a close relationship.

Authors:  Giorgio Trivioli
Journal:  Intern Emerg Med       Date:  2019-07-17       Impact factor: 3.397

Review 2.  The Estimated Risk of Atrial Fibrillation Related to Alcohol Consumption.

Authors:  Michael A Rosenberg; Kenneth J Mukamal
Journal:  J Atr Fibrillation       Date:  2012-06-15

3.  The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up.

Authors:  Conn Sugihara; Nick Freemantle; Steven G Hughes; Steve Furniss; Neil Sulke
Journal:  J Interv Card Electrophysiol       Date:  2015-02-25       Impact factor: 1.900

4.  Inflammatory activation and endothelial dysfunction markers in patients with permanent atrial fibrillation: a cross-sectional study.

Authors:  Carlo Domenico Maida; Sonya Vasto; Domenico Di Raimondo; Alessandra Casuccio; Valerio Vassallo; Mario Daidone; Alessandro Del Cuore; Gaetano Pacinella; Anna Cirrincione; Irene Simonetta; Vittoriano Della Corte; Salvatore Rizzica; Giulio Geraci; Antonino Tuttolomondo; Antonio Pinto
Journal:  Aging (Albany NY)       Date:  2020-05-03       Impact factor: 5.682

5.  Left atrial enlargement in the early stage of hypertensive heart disease: a common but ignored condition.

Authors:  Guanhua Su; Heng Cao; Sudan Xu; Yongxin Lu; Xinxin Shuai; Yufei Sun; Yuhua Liao; Jingdong Li
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-02-20       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.